Osteoporosis and cardiovascular diseases
Ang presyon ng dugo ay isa sa mga pangunahing indikasyon ng kalusugan, na hindi lamang sumasalamin sa puso at sistema ng sirkulasyon, kundi pati na rin sa aktibidad ng mga bato, mga organo ng endokrin, paggawa ng dugo, at ng sistema ng nerbiyos. Kaya naman, walang isang unibersal na gamot laban sa mataas na presyon ng dugo. Hindi ka basta basta puwedeng pumunta sa botika at magtanong ng 'tableta para sa presyon,' kasi agad na tatanungin ng parmasyutiko – anong gamot ang nireseta sa iyo ng doktor?
УЗНАТЬ ПОДРОБНЕЕ >>>
Osteoporosis and cardiovascular diseases
Оглавление
- Описание Osteoporosis and cardiovascular diseases
- Эффект от применения
- Мнение специалиста
- Как заказать?
Описание Osteoporosis and cardiovascular diseases
Diuretiko (Diuretika) ay nagpapataas ng pag-ihi ng katawan, na nagreresulta sa pagbaba ng presyon ng dugo. Simpleng paliwanag: Ang tuloy-tuloy na pag-ihi ng katawan ay nagdudulot ng pagbaba ng dami ng plasma sa dugo at sa gayon ay mas kaunting likido sa mga ugat — bumababa ang presyon sa mga pader ng ugat. Una sa lahat, ang mga Beta-blocker ay karaniwang ibinibigay sa mga pasyente na may heart failure, aortic aneurysm, pagkatapos ng myocardial infarction, at sa mga kababaihan na nasa edad ng pagbubuntis, lalo na sa mga kababaihang nagpaplano ng pagbubuntis. Madalas matanggap ng katawan ang Beta-blocker, pero maaari rin itong magdulot ng pantal sa balat at bradycardia – sobrang bagal ng tibok ng puso.
Osteoporosis and cardiovascular diseases: A neglected relationships In recent years, the research increasingly with the connection between osteoporosis and cardiovascular disease (CVD). Although this disease, pictures appear to be at first glance completely different point epidemiological studies on common risk factors and pathophysiological mechanisms. Definition and epidemiology Osteoporosis is a systemic skeletal disease that is characterized by a decrease in bone density and deterioration of bone architecture. This leads to an increased risk of fractures, particularly of the hip, spine, and forearm. Worldwide, about 200 million people are estimated to be affected by osteoporosis. Cardiovascular diseases include a variety of diseases of the heart and blood vessels, including coronary heart disease, heart attack, stroke, and vascular disease. CVD is the leading cause of death worldwide. Common Risk Factors In the analysis of the two disease groups, several common risk factors can be identified: Age: the risk for osteoporosis as well as for CVD increases significantly with age. Gender: women after the Menopause are due to the rapid drop in estrogen levels to an increased risk for osteoporosis; in addition, women in old age, a significantly increased risk for cardiovascular events. Style: Lack of physical activity, unhealthy diet, Smoking and excessive alcohol consumption life increase the risk for bone density loss as well as circulatory problems. Inflammation: Chronic low-threshold inflammatory processes play a role in the pathogenesis of both disease groups. Metabolic disorders: Diabetes mellitus, and metabolic syndrome are associated with an increased risk for osteoporosis as well as for CVD. Pathophysiological Connections Dieuchere research suggest that the Regulation of calcium and phosphate, which are important for bone homeostasis is of Central importance, also have a direct effect on the vessel wall and atherosclerosis development. In particular, the role of Vitamin D is intensively discussed: A deficiency of Vitamin D is associated with lower bone density and an increased risk for hypertension and congestive heart failure. In addition, studies show that the patients with osteoporosis often have an increased vascular stiffness and atherosclerosis. This could be due to common molecular pathways that control bone resorption as well as vascular calcification. Clinical Implications The recognisable link between osteoporosis and CVD has important clinical consequences: Early diagnosis: patients with the two diseases should be systematically for the Presence of the other investigated. Multidisciplinary care: The treatment should be interdisciplinary in nature, for example, through the cooperation of cardiologists, endocrinologists and orthopaedic surgeons. Style modification: health‑ promoting measures such as regular physical activity, a balanced diet with adequate calcium and Vitamin D content, as well as the lack of Smoking and excessive alcohol consumption can reduce the risk for both diseases. Drug therapy: Some of the medicines used for the treatment of osteoporosis, have shown promising effects on cardiovascular health, which needs to be further investigated. Conclusion The connection between osteoporosis and cardiovascular disease is complex and multifactorial. The common risk factors and pathophysiological mechanisms suggest that an integrated prevention and treatment strategy is useful. Further research is necessary in order to understand the molecular basis of this Association and to develop innovative therapeutic approaches. Would you like me to make a certain section in more detail, or other aspects of adding?
Зачем нужен Osteoporosis and cardiovascular diseases
Una sa lahat, ang mga Beta-blocker ay karaniwang ibinibigay sa mga pasyente na may heart failure, aortic aneurysm, pagkatapos ng myocardial infarction, at sa mga kababaihan na nasa edad ng pagbubuntis, lalo na sa mga kababaihang nagpaplano ng pagbubuntis. Madalas matanggap ng katawan ang Beta-blocker, pero maaari rin itong magdulot ng pantal sa balat at bradycardia – sobrang bagal ng tibok ng puso. What diseases are cardiovascular List of drugs for high blood pressureWhat diseases are cardiovascular
List of drugs for high blood pressure
Diet in diseases of the cardiovascular System
Diet in diseases of the cardiovascular SystemМнение эксперта
Cardio Balance helps reduce blood fat levels by reducing the production of cholesterol and triglycerides in the body and improving the transportation of fats in the bloodstream. Отзывы о Osteoporosis and cardiovascular diseases
Алина: Ginagamit ito bilang biologically active na pampadagdag sa pagkain — dagdag na pinagmumulan ng mga bitamina — B2, B6, C, mga organikong asido — mansanas, succinic, glutamine. Mga sangkap: malic acid, succinic acid, glutamic acid, badan extract, ascorbic acid, bitamina B2, B6.
Как заказать?
Заполните форму для консультации и заказа Osteoporosis and cardiovascular diseases. Оператор уточнит у вас все детали и мы отправим ваш заказ. Через 3-7 дней вы получите посылку и оплатите её при получении.
Prayer against high blood pressure. Diet for high blood pressure. Which is the table in cardiovascular diseases. Face in cardiovascular diseases. Cardio Balance helps reduce blood fat levels by reducing the production of cholesterol and triglycerides in the body and improving the transportation of fats in the bloodstream.
Nililinis ang mga ugat na kailangang alagaan mula sa deposito at pinananatili ang kinakailangang lakas ng tibok ng puso!
Diseases of the heart note-circulation System
https://devt.emodas.cy/articles/527-unlike-high-blood-pressure-hypertension.html
http://types.poligonmz.ru/articles/47301-poster-of-cardiovascular-diseases.html
NSAIDs in cardiovascular disease: risks and clinical implications Non-steroidal anti-inflammatory Drugs (NSAIDs) are among the most commonly used drugs worldwide and are mainly used for the treatment of pain, inflammation and fever. Despite their wide distribution and OTC availability (over‑the‑counter) you are associated with a number of side effects, particularly in patients with existing cardiovascular disease (CVD). Pharmacological mechanisms of action and cardiovascular effects The effect of the NSAIDs is based on the inhibition of the Cyclooxygenase enzymes (COX‑1 and COX‑2), for the synthesis of prostaglandins responsible. Prostaglandins play an important role in the Regulation of vascular tone, platelet aggregation and Renal blood flow. The selective or non-selective inhibition of these enzymes can trigger the following cardiovascular effects: Increase in blood pressure through a reduction in vasodilator of prostaglandins and decreased renal function. Fluid retention: due to changes in renal perfusion and increased sodium retention. Thromboembolic events: in particular, in the case of selective COX‑2 inhibitors, which affect platelet function less, but the production of prostacyclin (PGI₂) in the vessel to inhibit walls. Epidemiological Evidence Several large observational studies and meta-analyses have shown that the intake is associated with the NSAIDs with an increased risk for cardiovascular events. In particular: an increased risk for myocardial infarction (MI), a higher incidence of stroke, an increase of congestive heart failure exacerbations, a possible risk for arrhythmic events. The risk seems to be dose and duration of intake and the specific NSAIDs to hang out. For example, it was described for Diclofenac significantly higher cardiovascular risk than for Naproxen. Risk groups Particularly patients with risk: of existing coronary heart disease (CHD), arterial hypertension, Diabetes mellitus, chronic renal failure Congestive heart failure. Also, elderly patients are exposed to due to Comorbidities and altered pharmacokinetics with an increased risk. Clinical Recommendations Before the regulation of NSAIDs, a careful Benefit-risk assessment should be performed, especially in patients with CVD or elevated cardiovascular risk profile. Recommendations include: The lowest effective dose for the shortest possible duration. Waiver of COX‑2‑selective inhibitors in patients with hollow cardiovascular risk. Preference for Naproxen in some cases, because it has a more favourable cardiovascular profile (but with an increased gastrointestinal risk). Regular monitoring of blood pressure, of renal function, and of Edema during therapy. Educating the patients about the symptoms of cardiovascular complications (e.g., chest pain, shortness of breath, sudden swelling). Conclusion NSAIDs can cause in patients with cardiovascular disease to significant cardiovascular side effects. An individual risk assessment in a differentiated Medicines selection and close Monitoring are crucial to ensure the safety of these drugs in clinical practice. Further research is needed to understand the long-term effects of various NSAIDs on the cardiovascular System.